ELAB vs. KRON, GANX, NBRV, EGRX, AADI, OCUP, EYEN, NXTC, CLNN, and DARE
Should you be buying Elevai Labs stock or one of its competitors? The main competitors of Elevai Labs include Kronos Bio (KRON), Gain Therapeutics (GANX), Nabriva Therapeutics (NBRV), Eagle Pharmaceuticals (EGRX), Aadi Bioscience (AADI), Ocuphire Pharma (OCUP), Eyenovia (EYEN), NextCure (NXTC), Clene (CLNN), and Daré Bioscience (DARE). These companies are all part of the "pharmaceutical preparations" industry.
Elevai Labs (NASDAQ:ELAB) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings.
In the previous week, Elevai Labs had 2 more articles in the media than Kronos Bio. MarketBeat recorded 3 mentions for Elevai Labs and 1 mentions for Kronos Bio. Kronos Bio's average media sentiment score of 1.57 beat Elevai Labs' score of 0.94 indicating that Kronos Bio is being referred to more favorably in the news media.
Kronos Bio has a consensus target price of $4.13, indicating a potential upside of 422.15%. Given Kronos Bio's higher possible upside, analysts clearly believe Kronos Bio is more favorable than Elevai Labs.
Elevai Labs has a net margin of -211.25% compared to Kronos Bio's net margin of -1,534.11%. Kronos Bio's return on equity of -68.67% beat Elevai Labs' return on equity.
22.2% of Elevai Labs shares are owned by institutional investors. Comparatively, 64.1% of Kronos Bio shares are owned by institutional investors. 23.4% of Kronos Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Elevai Labs has higher earnings, but lower revenue than Kronos Bio. Elevai Labs is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks.
Kronos Bio received 18 more outperform votes than Elevai Labs when rated by MarketBeat users.
Summary
Kronos Bio beats Elevai Labs on 11 of the 15 factors compared between the two stocks.
Get Elevai Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevai Labs Competitors List
Related Companies and Tools
